http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2022516314-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6903 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4738 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2020-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2022516314-A |
| titleOfInvention | Persistent topical drug levels for innate immune agonists |
| abstract | The present invention relates to a water-insoluble controlled release pattern recognition receptor agonist (“PRRA”) or a pharmaceutically acceptable salt thereof for use in the treatment of cell proliferation disorders, or such a water-insoluble controlled release PRRA or the like thereof. A water-insoluble control that is a pharmaceutical composition comprising a pharmaceutically acceptable salt, administered by tissue administration, and at least 25% of the amount of PRRA remains topical in the tissue 3 days after administration. With respect to release PRRAs, pharmaceutically acceptable salts or pharmaceutical compositions thereof; and related embodiments. [Selection diagram] None |
| priorityDate | 2019-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1766.